Md. Code, Ins. § 15-1617
Md. Code, Ins. § 15-1617
Maryland · Maryland Code, Insurance · Status: effective
Cite this
- Citation
- Md. Code, Ins. § 15-1617, Maryland, version 1 as recorded 2026-09-29, yourstate.us, https://yourstate.us/provision/1779697
- Permanent ID
ys:prov:1779697@1- SHA-256
48b9211877d50bbbb38d598379ab6875c3a09d5b860b5f385351616dac840bd0
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
A pharmacy benefits manager shall ensure that its pharmacy and therapeutics committee has:
(1) policies and procedures, including disclosure requirements, to address potential conflicts of interest that members of the pharmacy and therapeutics committee may have with developers or manufacturers of prescription drugs;
(2) a process to evaluate medical and scientific evidence concerning the safety and effectiveness of prescription drugs, including available comparative information on clinically similar prescription drugs, when deciding what prescription drugs to recommend to include on a formulary;
(3) a process to evaluate medical and scientific evidence concerning the safety and effectiveness of prescription drugs when recommending utilization review requirements, dose restrictions, and step therapy requirements; and
(4) a process to enable the pharmacy and therapeutics committee to consider the need to recommend a formulary change to a purchaser in a timely manner but at least annually.